Biologics

A three-year study of Creative Medical Technology Holdings' StemSpine procedure found it was effective for addressing chronic lower back pain.

Orthobiologics company DiscGenics shared data supporting its IDCT (rebonuputemcel) allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease.

Apex Biologix has chosen Jim Rogers to be the company's next CEO. 

ChitogenX, formerly OrthoRTI, shared its third quarter results for fiscal year 2023.

Here are five top-read Becker's headlines on orthobiologics and regenerative medicine in 2022:

A study published in Neurology International found fusion rates of 98.6 percent with Orthofix's Trinity Elite cellular bone allograft, the devicemaker said Dec. 22.

NorthBay Health Orthopedics in Vacaville, Calif. added platelet-rich plasma injections for knee injuries, according to a Dec. 18 announcement in the Daily Republic.

Here are five updates in the orthobiologics industry since Oct. 17:

Shriners Children's Hawaii in Honolulu is the first hospital in the state to use the Bridge-Enhanced ACL Restoration, or BEAR, implant, ABC affiliate KITV reported Nov. 23.

Swedish-based bone graft substitute manufacturer Bonesupport, which received FDA approval for its bone infection indicator Cerament G in May, has found that the new product saves an average of $28,000 per patient according to a Nov. 21 email sent to…